The Trump administration is closing a loophole that drugmakers could use to avoid negotiations when they add active ingredients to drugs. It's also codifying regulations.
Joshua Cohen is an independent healthcare analyst. He specializes in healthcare policy, drug pricing, and reimbursement, with a strong focus on consumer health, public health, and digital health. His work has been featured in notable publications such as The New Yorker, Salon Media Group, Inc., and Forbes.













